Premise: An analysis of the costs and benefits of the rule was conducted by the Food and Drug Administration (FDA) and published in the notice of proposed rulemaking on August 11, 1995, and is contained in the preamble to the final rule.

Hypothesis: The FDA surrendered the cost-benefit analysis of the rule to another agency.
Relation: contradiction